Clinical trial · Observational
From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immunotherapy
NCT06273878CI-TRIAL-00074269unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non-interventional retro-prospective study on Endometrial tissue samples taken from surgically treated patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Validate the differential expression of LOX-1 and NALP3 receptors.
- timeFrame
- 36 months
- description
- Validate the differential expression of LOX-1 and NALP3 receptors at different steps progression of endometrial cancer; identify immune signatures shared between using transcriptomics the maternal-fetal interface and the different stages of progression of endometrial cancer; investigate their role functional in the immune escape process in endometrial carcinoma and/or in the pro-inflammatory response.
Secondary outcomes (2)
- measure
- Characterize phenotypic alterations.
- timeFrame
- 36 months
- description
- Characterize the phenotype and functional alterations of multiple candidate biomarkers relevant selected in AIM1 (surface antigens / cytokines / molecular pathways), a level of the cells of the immune infiltrate, in the different stages of cancer progression to the endometrium.
- measure
- Evaluate the predictive and/or prognostic value.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>18 years; * Histological diagnosis of endometrial hyperplasia with and without atypia, carcinoma of the endometrium histotype endometrioid at any stage of the disease (FIGO I-IV), patients subjected to hysterectomy for benign extra-endometrial pathology, patients with recurrence/metastasis from endometrioid endometrial carcinoma that are subjected to surgery; * Adequate biological material to be able to carry out the analyzes previously described; * Written informed consent (only for patients in the prospective part and/or in follow-up); * For the retrospective part: availability of samples adequately stored at the Institute biobank and availability of follow-up data. Exclusion Criteria: * Comorbidities not controlled with adequate medical therapy; * Infections of the endometrial cavity (pyometra); * Synchronous tumors; * Neoadjuvant treatments; * Previous radiation treatments on the pelvic region.
References
Publications (0)
Data not yet available
No reference posted for this study.